%0 Journal Article
%A Goldschmidt, Hartmut
%A Baertsch, Marc-Andrea
%A Schlenzka, Jana
%A Becker, Natalia
%A Habermehl, Christina
%A Hielscher, Thomas
%A Raab, Marc-Steffen
%A Hillengass, Jens
%A Sauer, Sandra
%A Müller-Tidow, Carsten
%A Luntz, Steffen
%A Jauch, Anna
%A Hose, Dirk
%A Seckinger, Anja
%A Brossart, Peter
%A Goerner, Martin
%A Klein, Stefan
%A Schmidt-Hieber, Martin
%A Reimer, Peter
%A Graeven, Ullrich
%A Fenk, Roland
%A Haenel, Mathias
%A Martin, Hans
%A Lindemann, Hans W
%A Scheid, Christoph
%A Nogai, Axel
%A Salwender, Hans
%A Noppeney, Richard
%A Besemer, Britta
%A Weisel, Katja
%T Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
%J Leukemia
%V 35
%N 4
%@ 1476-5551
%C London
%I Springer Nature
%M DKFZ-2020-01497
%P 1134-1144
%D 2021
%Z 2021 Apr;35(4):1134-1144
%X The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32694619
%R 10.1038/s41375-020-0948-0
%U https://inrepo02.dkfz.de/record/157227